CoChat

Characterization of human cytochrome P450 enzymes catalyzing domperidone N‐dealkylation and hydroxylation in vitro

Open access
Ward, Bryan A., Morocho, Alan, Kandil, Abdullah, Galinsky, Raymond E., Flockhart, David A., Desta, Zeruesenay · 2004 · British Journal of Clinical Pharmacology
Cited by 51

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Aims: To confirm the identity of the major metabolites of domperidone and to characterize the cytochrome P450s (CYPs) involved in their formation. Methods: Human liver microsomes (HLMs) were used to characterize the kinetics of domperidone metabolism and liquid chromatography‐mass spectrometry to identify the products. Isoform‐specific chemical inhibitors, correlation analysis and expressed human CYP genes were used to identify the CYPs involved in domperidone oxidation. Results: In HLMs, domperidone underwent hydroxylation to form 5‐hydroxydomperidone (MIII) and N‐dealkylation to form 2,3‐dihydro‐2‐oxo‐1H‐benzimidazole‐1‐propionic acid (MI) and 5‐chloro‐4‐piperidinyl‐1,3‐dihydro‐benzimidazol‐2‐one (MII). The formation of all three metabolites (n = 4 HLMs) followed apparent Michaelis‐Menten kinetics. The mean Km values for MI, MII and MIII formation were 12.4, 11.9, and 12.6 µm, respectively. In a panel of HLMs (n = 10), the rate of domperidone (5 µm and 50 µm) metabolism correlated with the activity of CYP3A (r > 0.94; P < 0.0001). Only ketoconazole (1 µm) (by 87%) and troleandomycin (50 µm) (by 64%) inhibited domperidone (5 µm) metabolism in HLMs. Domperidone (5 and 50 µm) hydroxylation and N‐dealkylation was catalyzed by expressed CYP3A4 at a higher rate than the other CYPs. CYP1A2, 2B6, 2C8 and 2D6 also hydroxylated domperidone Conclusions: CYP3A‐catalyzed N‐dealkylation and aromatic hydroxylation are the major routes for domperidone metabolism. The drug would be expected to demonstrate highly variable bioavailability due to hepatic, and possibly intestinal first‐pass metabolism after oral administration. Increased risk of adverse effects might be anticipated during concomitant administration with CYP3A inhibitors, as well as decreased efficacy with inducers of this enzyme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2004.02156.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 51

Metadata

Authors
Ward, B. A., Morocho, A., Kandil, A., Galinsky, R. E., Flockhart, D. A., & Desta, Z.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2004-06-21
Volume
58
Issue
3
Pages
277-287
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2049902803
Cited by
51
References
1
FWCI
0.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of human cytochrome P450 enzymes catalyzing domperidone N‐dealkylation and hydroxylation in vitro. https://app.cochat.ai/papers/10.1111/j.1365-2125.2004.02156.x
The paper
Ward, B. A., Morocho, A., Kandil, A., Galinsky, R. E., Flockhart, D. A., & Desta, Z. (2004). Characterization of human cytochrome P450 enzymes catalyzing domperidone N‐dealkylation and hydroxylation in vitro. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2004.02156.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.